Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review

Matejka Rebolj, postdoctoral researcher,1 Jesper Bonde, senior researcher,2,3 Sisse Helle Njor, postdoctoral researcher,1 Elsebeth Lynge, professor of epidemiology1

ABSTRACT
Objective To determine the trade-off between the sensitivity and the specificity for high grade cervical intraepithelial neoplasia at hybrid capture 2 cut-off values above the standard ≥1 relative light units/cut-off level (rlu/co).

Design Systematic review.

Data sources PubMed.

Study selection Randomised controlled trials in primary cervical screening using hybrid capture 2 testing in the intervention arms. Articles published until August 2010 were included if the numbers of women with positive test results and with cervical intraepithelial neoplasia were stratified by hybrid capture 2 cut-off levels.

Participants Women in the baseline screening rounds of the trials.

Interventions Hybrid capture 2 screening in the baseline round including the diagnostic follow-up as practised in the randomised controlled trials and as reported by hybrid capture 2 cut-off values.

Results Owing to heterogeneity in the trials, meta-analysis was not possible. Including cut-off values up to ≥10 rlu/co, 25 observation points were available for analysis. The relative sensitivity for cervical intraepithelial neoplasia grade III or higher at cut-off levels of ≥2, ≥4 or ≥5, and ≥10 rlu/co compared with a cut-off level of ≥1 rlu/co varied by trial, but at their lowest they were 0.97, 0.92, and 0.91, respectively. A similar pattern was observed for cervical intraepithelial neoplasia grade II or higher. The specificity would increase by at least 1%, 2%, and 3%, respectively, so that up to 24%, 39%, and 53%, of positive hybrid capture 2 test results not associated with high grade neoplasia could be avoided. Only two outliers existed to this general pattern.

Conclusions Although the data were derived from the baseline screening rounds only, the decrease in the sensitivity for high grade cervical intraepithelial neoplasia using a hybrid capture 2 cut-off level between ≥2 rlu/co and ≥10 rlu/co seemed acceptable given the international recommendations for testing for human papillomavirus DNA in cervical screening, which require 90% or more sensitivity for cervical intraepithelial neoplasia grade II or higher compared with hybrid capture 2 at ≥1 rlu/co. The data suggest that the hybrid capture 2 cut-off level could be increased in primary screening; this seems reasonably safe and is significantly less burdensome for women.

INTRODUCTION
The purpose of cervical screening is to decrease the burden of cervical cancer. Since the 1960s, cytology based cervical screening has led to major reductions in the incidence of cervical cancer and related mortality.1 The method is not highly sensitive, however, and several countries, including the United Kingdom, are considering making the transition to human papillomavirus based screening. Although infection with high risk human papillomavirus is a necessary step in the development of cervical cancer, most infections clear spontaneously. Consequently a diagnosis of an infection is on its own not adequately specific for identification of progressive cervical intraepithelial neoplasia.2 This may increase the need for repeated testing and the workload for general practitioners and gynaecologists.3 To maximise the benefit of testing for human papillomavirus DNA in cervical screening, a practical diagnostic algorithm that avoids positive human papillomavirus findings in women with no or inconsequential cervical intraepithelial neoplasia is therefore warranted.

Hybrid capture 2 (Qiagen, Gaithersburg, Maryland) using the threshold of ≥1 relative light units/cut off (rlu/co) is a clinically validated US Food and Drug Administration approved test for detection of human papillomavirus DNA, with a high sensitivity for high grade cervical intraepithelial neoplasia. Compared with cytology, hybrid capture 2 has an estimated relative sensitivity for detection of cervical intraepithelial neoplasia grade III or higher of 1.32 (95% confidence interval 1.06 to 1.64).4 Hybrid capture 2 detects DNA from 13 human papillomavirus genotypes—16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68—which of which 12 are considered to be high risk for humans and one probably carcinogenic.5 Recommendations for screening women aged 30 or more use the hybrid capture 2’s levels of sensitivity for cervical intraepithelial
neoplasia grade II or higher, its specificity, and its reproducibility as a standard to which new tests for human papillomavirus DNA should be compared.\textsuperscript{4} To avoid positive hybrid capture 2 test results not associated with neoplasia, several authors have evaluated hybrid capture 2 screening strategies with the cut-off level for a positive test result above the standard ≥ 1 rlu/co. These authors assessed the trade-offs between a decrease in the sensitivity, measured as the detection of cervical intraepithelial neoplasia, and an improvement in the specificity, measured as the test’s positive predictive value. For example, using the hybrid capture 2 with a cut-off level of ≥ 1 rlu/co among women aged 35 to 60 in the combined Italian phases 1 and 2 randomised controlled trials, the sensitivity for cervical intraepithelial neoplasia grade III or higher was significantly increased compared with cytology: relative sensitivity 1.52 (95% confidence interval 1.06 to 2.19). The positive predictive value was significantly lower: relative positive predictive value 0.63 (95% confidence interval 0.44 to 0.89). Using the cut-off level of ≥ 2 rlu/co, the relative sensitivity was similar, at 1.50 (1.04 to 2.16), whereas the relative positive predictive value increased to 0.81 (0.56 to 1.15).\textsuperscript{7} Similar studies have been undertaken, using data from other randomised controlled trials.\textsuperscript{6-10}

The studies have not produced a unanimous answer on whether and to what extent the cut-off level using the hybrid capture 2 could be increased. This may be related to several methodological factors. Firstly, some studies defined a positive test result as a referral for colposcopy, whereas others accounted for all women recommended for follow-up.\textsuperscript{3} These differences in the definition of a positive screening test result make a comparison across studies difficult. Secondly, the outcomes at increased hybrid capture 2 thresholds were typically compared with the outcomes of cytology screening, and as the sensitivity of cytology varies among laboratories this type of evaluation may not allow a generalised conclusion on the optimal cut-off level using hybrid capture 2. Finally, several studies observed screening outcomes at a single increased hybrid capture 2 cut-off level (for example, ≥ 2 rlu/co)\textsuperscript{9} rather than across a wider range. We systematically determined the trade-offs between the sensitivity and the specificity for detection of cervical intraepithelial neoplasia for hybrid capture 2 at a range of increased cut-off levels compared with the standard ≥ 1 rlu/co. We focused on published data derived from baseline screening rounds of the randomised controlled trials using hybrid capture 2 in primary cervical screening because these population based data have been in the forefront of the currently ongoing discussions on the future of cervical screening. In contrast with previous studies, we used standard methods to ensure that the outcomes could be compared.

**METHODS**

We used PubMed to search for data published until the end of August 2010 deriving from randomised controlled trials using tests for the detection of human papillomavirus DNA in primary cervical screening. To improve the sensitivity for relevant articles we adopted a two step search strategy. The first step was used to identify all randomised controlled trials using human papillomavirus DNA tests in primary screening populations. The second step was used to obtain a comprehensive overview of articles published from the identified randomised controlled trials. For this search we used trial acronyms if these were listed in the identified randomised controlled trials.\textsuperscript{11-17} Otherwise we also searched under the names of the principal investigators, contacts for the trial, or heads of organisations running the trials.\textsuperscript{11,17} In both steps we screened the retrieved abstracts to identify all potentially relevant papers, for which we subsequently retrieved full text publications. See web extra for the search strategies for both steps.

**Statistical analysis**

Owing to various differences in the designs of the trials\textsuperscript{18} we refrained from carrying out a traditional meta-analysis and opted for a separate presentation of the results from each trial in a structured format. Using a prespecified table format (table 1), two researchers independently retrieved the numbers of women included in the trials, those with a positive hybrid capture 2 test result, and those with histologically diagnosed cervical intraepithelial neoplasia grades I, II, and III or higher at each reported cut-off level and for each reported age group. Information on follow-up procedures and on ascertainment of cervical intraepithelial neoplasia was also obtained during this process.

We defined a hybrid capture 2 test result as positive if any test was at or above the analysed cut-off level, regardless of the subsequent follow-up recommendations (immediate colposcopy or repeated testing).\textsuperscript{3} We defined a positive test result not followed by a diagnosis of the studied cervical intraepithelial neoplasia as a false positive. If followed up properly, these women would all have undergone repeated testing or colposcopy. We calculated, by grade of cervical intraepithelial neoplasia, the detection rates (numbers of women with detected neoplasia per 100 000 women), the relative sensitivity, the relative specificity, and the relative risks of false positive test results at increased hybrid capture 2 cut-off levels, using the number of women with positive test results and the detection of cervical intraepithelial neoplasia at ≥ 1 rlu/co as the reference values. The 95% confidence intervals were calculated by assuming a binomial distribution of the studied events.

**RESULTS**

The first step of the search identified 275 articles (fig 1). After screening of the abstracts, 35 full text articles were retrieved. Eleven randomised controlled trials that used testing for human papillomavirus DNA in primary screening were identified this way. Two of the trials\textsuperscript{20,21} did not use hybrid capture 2 and one included a selected group of women who had not responded to previous invitations.\textsuperscript{21} These three trials were excluded from further searches. For the remaining
null
intraepithelial neoplasia grade III or higher and for grade II or higher was closer to 1.

At cut-off level ≥4 rlu/co (≥5 rlu/co in the Finnish trial), the relative sensitivity for cervical intraepithelial neoplasia grade III or higher ranged between 0.92 in the Italian phase 1 trial (35-60 years) and 1.00 in the Italian phase 1 trial (25-34 years). The relative sensitivity for cervical intraepithelial neoplasia grade II or higher in the Italian phase 2 trial (35-60 years) was 0.87. In other trials, the relative sensitivity for cervical intraepithelial neoplasia grade II or higher ranged between 0.95 (UK, Italian phase 1 (35-60 years), Finland) and 0.97 (Italian phase 2, 25-34 years).

At cut-off level ≥10 rlu/co, the relative sensitivity for cervical intraepithelial neoplasia grade III or higher was the lowest in the Italian phase 2 trial (35-60 years), at 0.83. In other trials, the relative sensitivity for cervical intraepithelial neoplasia grade III or higher varied between 0.91 (Finland) and 0.96 (Italian phase 2, 25-34 years). The relative sensitivity for cervical intraepithelial neoplasia grade II or higher was again the lowest in the Italian phase 2 trial (35-60 years), at 0.74, whereas in the other trials it ranged between 0.91 (UK, Italian phase 1 (25-34 years), Finland) and 0.94 (Italian phase 2, 25-34 years). At higher cut-off levels in the Finnish trial, the relative sensitivity for any grade of cervical intraepithelial neoplasia decreased substantially.

The relative sensitivity for cervical intraepithelial neoplasia grade I tended to be more substantially decreased at increased cut-off level, although more so in the Italian trials than in the Finnish trial (table 3). At cut-off level ≥4 rlu/co (≥5 rlu/co in the Finnish trial), the relative sensitivities for cervical intraepithelial neoplasia grade I were 0.92 and 0.84 in the Italian phases 1 and 2 trials (25-34 years), 0.72 and 0.66 in the Italian phases 1 and 2 trials (35-60 years), and 0.96 in the Finnish trial. At cut-off level ≥10 rlu/co the relative sensitivities were 0.83, 0.74, 0.55, 0.52, and 0.91, respectively.

Relative specificity for cervical intraepithelial neoplasia by hybrid capture 2 cut-off level
At all increased cut-off levels, the specificity for cervical intraepithelial neoplasia grade III or higher increased significantly (table 3, web extra figure). At cut-off level ≥2 rlu/co, the specificity increased within a range of 1% (Italian phase 2 (35-60 years), and Finland) and 3% (UK trial). At cut-off level ≥4 rlu/co (≥5 rlu/co in Finland), the specificity increased within a range of 2% (Italian phase 2, 35-60 years) and 5% (UK trial), and at cut-off level ≥10 rlu/co it increased within a range of 3% (Italian phase 2, 35-60 years) and 7% (UK trial). Similar numbers were found for cervical intraepithelial neoplasia grade II or higher as end point.

These gradual increases in the specificity were reflected in the considerably reduced risks of false positive hybrid capture 2 test results (fig 3). When cervical intraepithelial neoplasia grade III or higher was used as an end point, for example, the relative proportions compared with ≥1 rlu/co at cut-off level ≥10 rlu/co were 0.68 and 0.67 in the Italian phases 1 and 2 trials (25-34 years), 0.59 in the UK trial, 0.47 and 0.51 in the Italian phases 1 and 2 trials (35-60 years), and 0.53 in the Finnish trial. Similar results were obtained for other grades of cervical intraepithelial neoplasia (data not shown).

**DISCUSSION**

Recently published international recommendations for screening women aged 30 or more for human papillomavirus require that new tests to detect human papillomavirus DNA show at least a 90% sensitivity for cervical intraepithelial neoplasia grade II or higher compared with the sensitivity of hybrid capture 2 testing using the cut-off level ≥1 rlu/co, and according to Kinney et al, the sensitivity of human papillomavirus screening for cervical intraepithelial neoplasia grade II or higher should be above 90%.

Our reanalysis of the reported trial data showed that hybrid capture 2 testing using the range of increased cut-off levels between ≥2 rlu/co and ≥10 rlu/co is able to meet...
Table 2 | Reported data on follow-up procedures from randomised controlled trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>Acronym</th>
<th>Age range (years)</th>
<th>No in intervention arm</th>
<th>Follow-up recommendations after positive hybrid capture 2 test result (≥1 rlu/co)</th>
<th>Compliance with follow-up recommendations</th>
<th>Reported histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Italian phase 1</td>
<td>NTCC 1</td>
<td>25-34</td>
<td>6002</td>
<td>Cytology normal: repeat testing at 12 months; atypical squamous cells of undetermined significance or worse: colposcopy</td>
<td>Cytology normal: 62%; atypical squamous cells of undetermined significance or worse: 94%</td>
<td>Consensus diagnosis ≥1 year of referral for colposcopy (immediate or after repeated testing)</td>
</tr>
<tr>
<td>Italian phase 1</td>
<td>NTCC 2</td>
<td>25-34</td>
<td>6937</td>
<td>Colposcopy</td>
<td>94%</td>
<td>Consensus diagnosis ≥1 year of referral for colposcopy (immediate or after repeated testing)</td>
</tr>
<tr>
<td>UK trial</td>
<td>ARTISTIC</td>
<td>20-64</td>
<td>24 510</td>
<td>Intervention arm: cytology normal: repeat testing at 12 months; borderline or mildly abnormal: repeat testing at six months; moderately abnormal or worse: colposcopy</td>
<td>Intervention arm: cytology normal: 55%. Other: NA</td>
<td>Worst diagnosis in ≤30 months of abnormal round 1 sample</td>
</tr>
<tr>
<td>Italian phase 2</td>
<td>NTCC 1</td>
<td>35-60</td>
<td>16 706</td>
<td>Colposcopy</td>
<td>93%</td>
<td>Consensus diagnosis ≥1 year of referral for colposcopy (immediate or after repeated testing)</td>
</tr>
<tr>
<td>Italian phase 2</td>
<td>NTCC 2</td>
<td>35-60</td>
<td>17 724</td>
<td>Colposcopy</td>
<td>93%</td>
<td>Consensus diagnosis ≥1 year of referral for colposcopy (immediate or after repeated testing)</td>
</tr>
<tr>
<td>Finnish trial</td>
<td>NA</td>
<td>30-60</td>
<td>18 438</td>
<td>Cytology normal or atypical squamous cells of undetermined significance: repeat testing at 12 months; low grade squamous intraepithelial lesions† or worse: colposcopy</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

NA = not available.
*Intervention and control arm combined.
†Histology not reported for women with cytology less severe than low grade squamous intraepithelial lesions.

these requirements. Using the cut-off level ≥2 rlu/co instead of ≥1 rlu/co, up to 3% of cervical intraepithelial neoplasia grade II or higher and of grade III or higher detectable at cut-off level ≥1 rlu/co would not be detected at the given screen. Up to 8% of cervical intraepithelial neoplasia grade II or higher and of grade III or higher would not be detected at the given screen if the cut-off levels ≥4 or ≥5 rlu/co were used, and up to 9% if the cut-off level ≥10 rlu/co was used. The specificity of the hybrid capture 2 test was significantly increased with increased cut-off levels, reflecting a significantly reduced risk of false positive test results. At cut-off level ≥10 rlu/co, this risk was reduced by about one half among women aged 30 or more, whereas among younger women the reduction was about one third. The observed patterns were consistent across trials, with the only exception being the Italian phase 2 trial for women aged 35 to 60. In this trial, 17% of the cervical intraepithelial neoplasia grade III or higher would be missed at cut-off level ≥10 rlu/co. Owing to the relatively low number of cervical intraepithelial neoplasia grade II or higher and of grade III or higher reported from most trials, the calculated 95% confidence intervals for relative sensitivities were wide.

Limitations of the study

No reported data sufficiently stratified by hybrid capture 2 cut-off level could be identified from four randomised controlled trials, of which two were undertaken in previously unscreened women,25,26 one was not undertaken within an organised screening programme,5 and one has not yet completed its recruitment.22 The outcomes presented in this systematic review may therefore not be generalisable to settings with opportunistic screening and settings with previously unscreened women. Some of the data from the four trials included in this systematic review have been incompletely reported. For instance, data on lesions detected during the extended follow-up in the two Italian trials27 have not been reported by baseline cut-off levels, and data on lesions detected during follow-up with repeated testing of women with triage cytology less severe than low grade squamous intraepithelial lesions have not been reported by cut-off level from the Finnish trial.30 It could be argued that in the reported data from the Finnish trial, the detection of cervical intraepithelial neoplasia grade I was particularly low because only women positive for human papillomavirus and with at least low grade squamous intraepithelial neoplasia on cytology were referred for colposcopy.

Detection of cervical intraepithelial neoplasia depends on the follow-up procedures for women who were positive at hybrid capture 2 cut-off level ≥1 rlu/co, and these procedures varied by trial (table 2). In the Italian phase 2 trial, all of these women were immediately referred for colposcopy, whereas in the Italian phase 1 trial they were immediately referred for colposcopy only if they were older than 34 or had abnormal cytology, in the Finnish trial if the cytology was low grade squamous intraepithelial neoplasia or worse, and in the UK trial if the cytology was at least moderately abnormal. In trials with reported data, more than 90% of the immediately referred women had colposcopy. Women with a positive hybrid capture 2 test result not immediately referred for colposcopy were recommended to undergo repeated testing in six to 12 months, and only 55% in the UK...
Fig 2 | Percentage of women with positive hybrid capture 2 test results, and detection rates of cervical intraepithelial neoplasia grade III or higher (CIN III+) per 1000 women screened, by hybrid capture 2 cut-off level in intervention arms of reviewed randomised controlled trials (intervention+control arm in UK trial)

The authors concluded that using hybrid capture 2 testing with a cut-off level ≥10 rlu/co might be the most appropriate screening strategy for areas with basic screening infrastructure that does not allow frequent screening.

Recently, detailed results for a range of hybrid capture 2 cut-off levels were presented from a Dutch VUSA-screen cohort study of 25 871 women aged 30 to 60 screened with both hybrid capture 2 and cytology. In this study, the relative sensitivity for high grade cervical intraepithelial neoplasia and the relative risks of false positive test results with increased hybrid capture 2 cut-off levels were compared with the outcomes of cytology screening. Only women referred for colposcopy were taken into account in the calculation of the risk of false positive test results. This study could not identify any increased hybrid capture 2 cut-off level at which the colposcopy referral rate would be similar to that in cytology screening without at the same time substantially decreasing the test’s sensitivity for high grade cervical intraepithelial neoplasia. The authors consequently proposed to keep the ≥1 rlu/co cut-off level. We recalculated the VUSA-screen data using the hybrid capture 2 test with a cut-off level ≥1 rlu/co as a reference, and accounting for all positive screening test results in the calculation. At a cut-off level ≥10 rlu/co, the relative sensitivity for cervical intraepithelial neoplasia grade III or higher was 0.90 (131/146; 95% confidence interval 0.84 to 0.94) compared with cut-off level ≥1 rlu/co, and the corresponding relative risk of false positive test results was 0.64 (746/1157; 0.62 to 0.67). The relative sensitivity for cervical intraepithelial neoplasia grade II or higher was 0.89 (203/227; 0.85 to 0.93) and the corresponding
relative risk of false positive test results was 0.63 (674/1076; 0.60 to 0.65). Thus, the VUSA-screen data were in line with the data from the analysed randomised controlled trials, and in fact support using an increased hybrid capture 2 cut-off level in screening.

Effect on cervical intraepithelial neoplasia treatment and the psychosocial burden of screening

If the cut-off level was increased from ≥1 rlu/co to ≥10 rlu/co, up to 18 fewer women with cervical intraepithelial neoplasia grade III or higher per 100 000 screened women would be diagnosed and treated at the given screen in part of the Italian trials and in the Finnish trials. This number was 34 in the Italian phase 2 trial (35-60 years) and 90 in the UK trial, although in the case of the UK trial this still represented less than 10% of all detected cervical intraepithelial neoplasia grade III or higher at ≥1 rlu/co to ≥10 rlu/co. The rare prevalent cancer cases at a given screening round may, however, be at risk of being missed at any cut-off point.41

Even in women over 30, the use of human papillomavirus DNA tests would in many countries double the number of women with a positive screening test result compared with cytology.7 8 20 28 To help manage this increase, several authors have focused on finding optimal triage procedures to avoid excess referral for colposcopy and excess diagnoses, particularly of cervical intraepithelial neoplasia grade II.42 This is warranted, as colposcopy tends to be relatively expensive and induces anxiety.43 Furthermore, cervical intraepithelial neoplasia grade II is often regressive44 45 but nevertheless usually recommended for treatment that is warranted, as colposcopy tends to be relatively expensive and induces anxiety.43 Furthermore, cervical intraepithelial neoplasia grade II is often regressive44 45 but nevertheless usually recommended for treatment that may be associated with severe obstetric outcomes.46 Women with positive human papillomavirus test results who are not immediately referred for colposcopy are normally recommended for repeated testing. These repeated tests increase the workload of general practitioners or gynaecologists and affect women’s quality of life.47-49 The need for repeated tests could be substantially decreased by using an increased cut-off point. The risk of not detecting a small proportion of cervical intraepithelial neoplasia grade III at a given screening round should thus be interpreted in the light of substantially diminished overdiagnosis of harmless human papillomavirus infections in healthy women. The frequency of such infections can be well

<table>
<thead>
<tr>
<th>Trial (age range)</th>
<th>Hybrid capture 2 cut-off level (rlu/co)</th>
<th>Relative sensitivity (95% CI)</th>
<th>Relative specificity (95% CI)</th>
<th>Relative risk of false-positive tests (95% CI)</th>
<th>Cervical intraepithelial neoplasia grade III or higher</th>
<th>Cervical intraepithelial neoplasia grade II or higher</th>
<th>Cervical intraepithelial neoplasia grade I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Italian phase 1</td>
<td>≥1</td>
<td>1.00 (0.78 to 1.00)</td>
<td>0.87 (0.85 to 0.89)</td>
<td>1.00 (0.93 to 1.00)</td>
<td>1.00 (1.02 to 1.02)</td>
<td>0.93 (0.87 to 0.97)</td>
<td></td>
</tr>
<tr>
<td>(25-34)</td>
<td>2</td>
<td>1.00 (0.78 to 1.00)</td>
<td>0.87 (0.85 to 0.89)</td>
<td>0.93 (0.97 to 1.00)</td>
<td>1.00 (1.02 to 1.02)</td>
<td>0.93 (0.87 to 0.97)</td>
<td></td>
</tr>
<tr>
<td>Italian phase 2</td>
<td>≥1</td>
<td>0.93 (0.68 to 1.00)</td>
<td>0.68 (0.65 to 0.72)</td>
<td>0.91 (0.80 to 0.97)</td>
<td>1.05 (1.04 to 1.06)</td>
<td>0.83 (0.75 to 0.89)</td>
<td></td>
</tr>
<tr>
<td>(25-34)</td>
<td>2</td>
<td>0.93 (0.68 to 1.00)</td>
<td>0.68 (0.65 to 0.72)</td>
<td>0.91 (0.80 to 0.97)</td>
<td>1.05 (1.04 to 1.06)</td>
<td>0.83 (0.75 to 0.89)</td>
<td></td>
</tr>
<tr>
<td>UK trial</td>
<td>≥1</td>
<td>0.99 (0.97 to 1.00)</td>
<td>0.90 (0.97 to 1.00)</td>
<td>0.90 (1.01 to 1.04)</td>
<td>0.83 (0.75 to 0.89)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(20-64)</td>
<td>2</td>
<td>0.97 (0.86 to 1.00)</td>
<td>0.72 (0.70 to 0.73)</td>
<td>0.90 (0.97 to 1.03)</td>
<td>0.72 (0.63 to 0.80)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italian phase 1</td>
<td>≥1</td>
<td>0.97 (0.80 to 0.95)</td>
<td>0.59 (0.58 to 0.61)</td>
<td>0.91 (0.88 to 0.93)</td>
<td>1.07 (1.06 to 1.07)</td>
<td>0.74 (0.65 to 0.81)</td>
<td></td>
</tr>
<tr>
<td>(35-60)</td>
<td>2</td>
<td>0.92 (0.79 to 0.98)</td>
<td>0.51 (0.48 to 0.54)</td>
<td>0.93 (0.85 to 0.98)</td>
<td>1.04 (1.04 to 1.05)</td>
<td>0.55 (0.46 to 0.64)</td>
<td></td>
</tr>
<tr>
<td>Italian phase 2</td>
<td>≥1</td>
<td>0.97 (0.86 to 1.00)</td>
<td>0.72 (0.70 to 0.73)</td>
<td>0.90 (0.97 to 1.03)</td>
<td>0.72 (0.63 to 0.80)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(35-60)</td>
<td>2</td>
<td>0.94 (0.81 to 0.99)</td>
<td>0.52 (0.49 to 0.55)</td>
<td>0.92 (0.85 to 0.98)</td>
<td>1.04 (1.04 to 1.05)</td>
<td>0.55 (0.46 to 0.64)</td>
<td></td>
</tr>
<tr>
<td>Finnish trial</td>
<td>≥1</td>
<td>0.83 (0.66 to 0.93)</td>
<td>0.51 (0.48 to 0.54)</td>
<td>0.74 (0.62 to 0.84)</td>
<td>1.03 (1.03 to 1.03)</td>
<td>0.52 (0.42 to 0.62)</td>
<td></td>
</tr>
<tr>
<td>(30-60)</td>
<td>2</td>
<td>0.82 (0.60 to 0.95)</td>
<td>0.33 (0.31 to 0.36)</td>
<td>0.81 (0.70 to 0.89)</td>
<td>1.06 (1.05 to 1.06)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥250</td>
<td>0.36 (0.17 to 0.59)</td>
<td>0.16 (0.15 to 0.18)</td>
<td>0.42 (0.30 to 0.53)</td>
<td>0.77 (0.67 to 0.87)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥1000</td>
<td>0.23 (0.08 to 0.45)</td>
<td>0.05 (0.04 to 0.07)</td>
<td>0.29 (0.19 to 0.40)</td>
<td>0.01 (0.00 to 0.08)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
If the hybrid capture 2 cut-off level was increased from the standard ≥1 rlu/co to ≥10 rlu/co, the number of positive test results without underlying high grade cervical intraepithelial neoplasia would be about halved in women aged 30 years or more. The results suggest that it may be possible to increase the cut-off point used for the hybrid capture 2 test in screening without jeopardising its sensitivity for high grade cervical intraepithelial neoplasia, but considerably improving its specificity.

Conclusion

Increasing the cut-off level for a positive hybrid capture 2 test result above the standard ≥1 rlu/co is associated with a risk of not detecting some high grade cervical intraepithelial neoplasia as early as it would otherwise have been possible. The trade-offs between decreased sensitivity and increased specificity resulting from increasing the hybrid capture 2 cut-off level, however, seem acceptable according to the recent international recommendations on human papillomavirus DNA testing, and both younger and older women would benefit from this change. In the reported data from most reviewed trials, the relative sensitivity at increased cut-off levels for cervical intraepithelial neoplasia grade II or higher and for grade III or higher would still be 90% or more compared with ≥1 rlu/co. This was the case even when the hybrid capture 2 cut-off level was increased to ≥10 rlu/co. At this level, the improvement in the specificity led to about half as many women aged 30 or more and about one third fewer younger women with a false positive hybrid capture 2 test result compared with the standard cut-off level.

We thank Caspar Looman for statistical advice, Brian Larsen Thorsted for support on visual representation of the data, and Lene Borrits for operationalising the PubMed search strategy.

Contributors: MR and EL designed the study. MR, SHN, and EL analysed the data. All authors interpreted the results, drafted the manuscript, approved the decision to submit the manuscript, and had full access to all of the data in the study. MR is guarantor.

Funding: This work was supported by Olga and Esper Boel’s Fund; Aase and Ejnar Danielsen’s Fund; Augustinus Fund; Manufacturer Mads Clausen’s Fund; Family Hede Nielsen’s Fund; Else and Mogens Wedell-Wedelborg’s Fund; Carl and Ellen Hertz’s Grant for Danish Medical and Natural Sciences Research; and Merchant Sven Hansen and Mrs Ina Hansen’s Fund. None of these had any role in the study design, the collection of data, the analysis, the interpretation of the data, the writing of the paper, and in the decision to submit the paper for publication.

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: support from the Olga and Esper Boel’s Fund; Aase and Ejnar Danielsen’s Fund; Augustinus Fund; Manufacturer Mads Clausen’s Fund; Family Hede Nielsen’s Fund; Else and Mogens Wedell-Wedelborg’s Fund; Carl and Ellen Hertz’s Grant for Danish Medical and Natural Sciences Research; and Merchant Sven Hansen and Mrs Ina Hansen’s Fund; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; JB, MR, and EL are currently undertaking a comparative study of new generation human papillomavirus tests, involving collaboration with Roche Diagnostics, Genometica, Quagen Gaithersburg, and GenProbe.

Ethical approval: Not required.

Data sharing: No additional data available.